NPPA exempts Biodeal’s indigenously developed midazolam nasal spray from price

SENSEX 77,301.40

+ 383.55

NIFTY 23,960.60

+ 149.75

CRUDEOIL 8,703.00

 -401.00

GOLD 142,455.00

+ 3,003.00

SILVER 185,950.00

+ 6,252.00

SENSEX 77,301.40

+ 383.55

NIFTY 23,960.60

+ 149.75

NIFTY 23,960.60

+ 149.75

CRUDEOIL 8,703.00

 -401.00

CRUDEOIL 8,703.00

 -401.00

GOLD 142,455.00

+ 3,003.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

Midazolam 1.25 per cent w/v nasal spray is a prescription rescue medicine used primarily for the emergency treatment of acute repetitive seizures

By BL New Delhi Bureau

Updated - November 04, 2026 at 10:16 PM.

The National Pharmaceutical Pricing Authority (NPPA) has exempted Biodeal Pharmaceuticals Limited’s indigenously developed Midazolam Nasal Spray 1.25% w/v from the provisions of the Drugs (Prices Control) Order (DPCO), 2013, for five years, allowing the company to fix its own prices for the formulation during this period.

Midazolam 1.25 per cent w/v nasal spray is a prescription rescue medicine used primarily for the emergency treatment of acute repetitive seizures and seizure clusters, as well as for pre-procedure sedation. 

The exemption will be effective retrospectively from May 5, 2025, the date on which the Central Drugs Standard Control Organisation (CDSCO) granted marketing approval for the formulation.

In an order dated November 2, 2026, the NPPA said it considered the recommendations of its Multidisciplinary Committee (MDC) at its 153rd meeting held on October 29 before approving the exemption.

Epilepsy Medicine

Biodeal claims to be the first company in India to receive permission from the Drugs Controller General of India (DCGI) for Midazolam Nasal Spray. According to the company, the DCGI also confirmed that no other strength of midazolam nasal spray had been approved in India before this grant.

The formulation has been developed indigenously through the company’s in-house research and development programme. Midazolam is an anti-epileptic drug used in the management of seizures. The nasal spray is intended to provide a non-invasive rescue option during seizure emergencies, particularly in situations where intravenous or intramuscular administration may not be immediately possible.

According to Biodeal, the spray has an onset of action within five minutes and uses a metered-dose delivery system to ensure consistency in drug administration. The company says its U-shaped bottle design is intended to deliver the full dose, including the last drop. The formulation comes in a 1.25 per cent w/v strength, with four metered doses in a 1.2 ml bottle.

Declarations

Under the five-year exemption, Biodeal will be required to inform the NPPA of the Price to Retailer (PTR) and Maximum Retail Price (MRP) fixed by the company by submitting a price list in Form V under the DPCO, 2013.

Three months before the exemption expires, the company will have to comply with the applicable ceiling price or seek retail price approval for the formulation, as required.

The exemption applies only to Midazolam Nasal Spray 1.25% w/v and does not extend to the company’s other products.

Published on November 4, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers